** Shares of drug developer Amylyx Pharmaceuticals AMLX.O rise 1.9% to $5.45 premarket
** Co announces late-stage trial design for its experimental GLP-1 antagonist treatment, avexitide, to treat a type of low blood sugar called post-bariatric hypoglycemia $(PBH)$
** PBH is a condition that affects approximately 8% of people who have undergone bariatric surgery- AMLX
** The trial is designed to evaluate FDA-agreed upon primary goal of reduction in hypoglycemia or low blood sugar events- AMLX
** Co expects to dose the first study participant in the first quarter of 2025, followed by expected completion of recruitment in 2025, and anticipates topline data in 2026
** The late-stage trial will test the efficacy and safety of avexitide in participants with PBH following gastric bypass surgery
** Up to last close, stock was down 63.7% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。